Small Cell Lung Cancer Clinical Trials in Beijing, Beijing Municipality
100 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 100 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled225 locationsNCT06345729
Recruiting
Phase 1Phase 2
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Small Cell Lung Cancer Extensive Stage
Merck Sharp & Dohme LLC170 enrolled31 locationsNCT07227597
Recruiting
Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AbbVie698 enrolled317 locationsNCT04928846
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled383 locationsNCT05920356
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 1Phase 2
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Solid TumorsER+ Breast CancerTriple Negative Breast Cancer(TNBC)+2 more
Jacobio Pharmaceuticals Co., Ltd.102 enrolled8 locationsNCT05490472
Recruiting
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT07026669
Recruiting
Phase 1
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
NSCLC (Advanced Non-small Cell Lung Cancer)
Peking University Cancer Hospital & Institute21 enrolled1 locationNCT06969612
Recruiting
Phase 1Phase 2
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.104 enrolled21 locationsNCT05276726
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Colorectal, CancerNon-small Cell Lung CancerKRAS P.G12C+1 more
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Peking University Cancer Hospital & Institute65 enrolled1 locationNCT06869239
Recruiting
Phase 3
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
Hansoh BioMedical R&D Company460 enrolled9 locationsNCT06498479
Recruiting
Not Applicable
Immuno-effect of Tα1 for Stage I NSCLC
Non-small Cell Lung Cancer
Yousheng Mao40 enrolled1 locationNCT06598839
Recruiting
Phase 2
Serplulimab Combined With CCRT for LS-SCLC.
Small Cell Lung Cancer
Peking Union Medical College Hospital96 enrolled1 locationNCT06295926
Recruiting
I-125 Seeds Implantation in the Treatment of Recurrent Lung Cancer After Radiotherapy
Non-small Cell Lung CancerBrachytherapy
Peking University Third Hospital30 enrolled1 locationNCT04071418